Previous 10 |
Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...
Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...